Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04293835
Other study ID # PekingUTH M2019387
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2019
Est. completion date February 1, 2020

Study information

Verified date March 2020
Source Peking University Third Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The diversity of definitions for the rectosigmoid junction is becoming a major obstacle to the standardization of optimal treatment of rectal cancers. The aim of this study was to determine the average height of the sigmoid take-off and its association with individual factors.

Patients diagnosed with rectal and sigmoid colon cancer in our center from January 2010 to December 2018 were retrospectively enrolled in the cancer group. The results of 200 controls without colorectal disease were also reviewed (normal group). The distance of different landmarks and margins of cancer from the anal verge were retrieved from computed tomography (CT), magnetic resonance imaging (MRI), and endoscopy findings.


Description:

Method Patients All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group. Data regarding clinical characteristics and radiological results were retrospectively extracted from the department's database. Patients who were found on endoscopy to have cancer more than 20 cm from the anal verge were not included. Patients who received emergency surgery or palliative surgery, patients with a previous history of pelvic surgery, and patients without extractable radiological examinations were also excluded.

To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.

Endpoints The sigmoid take-off is the radiological sign representing the transition from mesocolon to mesorectum. It was described as "the point that the surgeon felt there was mobility of the colon away from the vertebral column" . The point of the sigmoid take-off was determined by combining both the sagittal and axial planes in CT and MRI. The distance from the anal verge was measured in sagittal planes by curvilinear distances in accordance with the lumen of the rectum. The distances of the sacral promontory, third sacral segment, and superior and inferior margin of cancers from the anal verge were measured in both CT and MRI following the same standard. The distance of the anterior peritoneal reflection from the anal verge was also measured in MRI. CT and MRI scans were reviewed originally by a junior specialist, and the process of measurement was recorded in the form of photographs. All photographs were then reviewed simultaneously by a senior surgeon and a senior radiologist who were both on colorectal cancer with over fifteen years' experience and were blinded to clinical outcomes and endoscopy results. The data were accepted if both of the senior specialists agreed with the strategy of measurement. If either of the two senior specialists disagreed with the measurement of a certain patient, the strategy of the measurement would be adjusted by the junior specialist until a consensus was reached.

The heights of the superior and inferior margins of the cancers were compared with the heights of various anatomical landmarks in order to classify cancers into different groups according to different definitions of the rectum, and to determine how the distribution of cancers would vary using the different definitions. Both dual classifications (sigmoid colon cancer and rectal cancer) and triple classifications (sigmoid colon cancer, rectosigmoid cancer, and rectal cancer) were applied. In the dual classification, only the distance of the inferior margin of the cancer was compared with the height of certain landmarks. If the distance of the inferior margin was below the height of the landmark, the cancer would be classified as rectal cancer, otherwise, it would be classified as sigmoid colon cancer. In the triple classification, a cancer would be classified as rectal cancer if the height of its superior margin was below the height of the landmark. Rectosigmoid cancer represented cancers straddling the landmark. As in the dual classification, cancers, whose inferior margins were above the height of the landmark were defined as sigmoid colon cancers.

Statistical Analyses Demographic and clinicopathologic data were collected and analyzed in both the cancer group and the normal group. Mean values with standard deviation (SD) or median values with ranges were calculated as appropriate. The influence of factors sex and age on the distance of the sigmoid take-off in the normal group was evaluated by nonparametric statistics and Spearman's correlation analysis, respectively. The distances of the sigmoid take-off as measured in the MRIs of both groups were compared using propensity score matching method. Aside from age and sex, heights of sacral promontory, third sacral segment, and peritoneal reflection were included in constructing the propensity score. A 1:1 matching using both optimal and greedy algorithms without replacement was adopted with a caliper width of 0.1. Differences among results of CT, MRI, and endoscopy in the cancer group were tested using paired T-tests. Both univariate and multivariate linear regression analyses were carried out in both groups to explore the relationship between the height of the sigmoid take-off and individual factors including age, sex and body habitus. Selection of variables entering into the multivariable regression model was based on statistical significance (P< 0.100). All analyses were carried out with IBM SPSS Statistics version 22.0 for Windows. A two-tailed P value less than 0.05 was considered statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 835
Est. completion date February 1, 2020
Est. primary completion date December 1, 2019
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group. Patients who were found on endoscopy to have cancer more than 20 cm from the anal verge were not included. Patients who received emergency surgery or palliative surgery, patients with a previous history of pelvic surgery, and patients without extractable radiological examinations were also excluded.

Exclusion Criteria:

- Patients who were found on endoscopy to have cancer more than 20 cm from the anal verge were not included.

- Patients who received emergency surgery or palliative surgery, patients with a previous history of pelvic surgery, and patients without extractable radiological examinations were also excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Whether to have intestinal-related disease
All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.

Locations

Country Name City State
China General Surgery Department, Peking University Third Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

D'Souza N, de Neree Tot Babberich MPM, d'Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Glimelius B, Lacy A, Cervantes A, Glynne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the height of sigmoid take-off To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.The point of the sigmoid take-off was determined by combining both the sagittal and axial planes in CT and MRI. The distance from the anal verge was measured in sagittal planes by curvilinear distances in accordance with the lumen of the rectum. 2010.1 to 2018-12
Secondary The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge. The distances of the sacral promontory, third sacral segment, and superior and inferior margin of cancers from the anal verge were measured in both CT and MRI following the same standard. The distance of the anterior peritoneal reflection from the anal verge was also measured in MRI. 2010.1 to 2018-12
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A